Ronald Stafford Watts
Director/Miembro de la Junta en Wenkart Foundation .
Cargos activos de Ronald Stafford Watts
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Wenkart Foundation | Director/Miembro de la Junta | - | - |
Biosceptre International Ltd.
 Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Director/Miembro de la Junta | - | - |
Historial de carrera de Ronald Stafford Watts
Antiguos cargos conocidos de Ronald Stafford Watts.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ENERGY ACTION LIMITED | Director/Miembro de la Junta | 12/11/2015 | 30/06/2017 |
| Presidente | 14/10/2011 | 12/11/2015 | |
Biosceptre (Aust) Pty Ltd.
 Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Director/Miembro de la Junta | - | - |
Formación de Ronald Stafford Watts.
| The University of New South Wales | Undergraduate Degree |
| University of Cambridge | Doctorate Degree |
Estadísticas
Internacional
| Australia | 5 |
| Reino Unido | 3 |
Operativa
| Director/Board Member | 4 |
| Chairman | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ENERGY ACTION LIMITED | Commercial Services |
| Empresas privadas | 3 |
|---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
| Wenkart Foundation | |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
